OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
ConditionATTR Amyloidosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorAstraZeneca
About this trial
The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics, treatment patterns and selected clinical, economic, and humanistic outcomes (for example Health Related Quality of Life (HRQoL), Neuropathy impairment score, activities of daily living (ADL) assessments) in patients with ATTR amyloidosis, and to better understand how the disease is presented.
Eligibility criteria
Qualifiers
Patients aged >18 years at study index date AND
A reported diagnosis code for amyloidosis OR
A claim for ATTR-specific treatment OR
A positive biopsy for amyloidosis and positive immunostaining result of biopsy for ATTR
Disqualifiers
Evidence of primary (AL) and secondary (AA) amyloidosis AND/OR
At least one claim/procedure code for stem cell transplant or at least two claims/procedure codes for chemotherapy and autoimmune disease drugs which may represent AL (primary) or AA (secondary) amyloidosis treatments
Trial design
Treatments tested in this trial
- no intervention
Treatment groups
52,121 Participants
are divided into 6 treatment groups6
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov